Wooseok Han
Executive Vice President & Chief Scientific Officer Cyrus Therapeutics
Dr. Wooseok Han is the Chief Scientific Officer of Cyrus Therapeutics, based in Seoul, Korea. He began his industrial career in 2005 at Chiron in Emeryville, California, which was shortly thereafter acquired by Novartis, and went on to spend the next 15 years at the Novartis Institutes for BioMedical Research (NIBR). During his tenure at Novartis, Dr. Han established himself as a medicinal chemist with deep expertise in oncology and infectious diseases, working across both Emeryville, California, and Cambridge, Massachusetts.
Prior to joining industry, Dr. Han completed a postdoctoral fellowship at The Scripps Research Institute in the laboratory of Professor Dale L. Boger, where his research focused on the total synthesis of complestatin. He earned his Ph.D. in Organic Chemistry from the University of Toronto.
Earlier in his career, before pursuing scientific training and professional experience overseas, Dr. Han spent five years at the Hansol Paper Institute of Technology. He holds a B.S. in Chemistry from Yonsei University and an M.S. in Organic Chemistry from the Korea Advanced Institute of Science and Technology (KAIST) in South Korea.
Seminars
- Analyzing how CYRS1542 exhibits favorable ADME/PK properties with no apparent DDI liabilities and demonstrates potent antitumor activity in preclinical CDX and PDX models
- Exploring how neuroendocrine features, including high CRBN expression, are associated with increased sensitivity to CYRS1542, providing the rationale for focusing clinical development on patients with neuroendocrine cancers (e.g., SCLC, NEPC)
- Evaluating how CYRS1542 showed a broader in vitro therapeutic index and a favorable safety profile in GLP monkey toxicology studies, with no evidence of thrombocytopenia, supporting the initiation of the first-in-human study in December 2025
